Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer

Amelia E. Hochreiter, Hongling Xiao, Erin M. Goldblatt, Sergei M. Gryaznov, Kathy Miller, Sunil Badve, George W. Sledge, Brittney-Shea Herbert

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Purpose: Maintenance of telomeres by telomerase is critical for the continuing proliferation of most advanced cancer cells. Telomerase activity has been detected in the vast majority of cancer cells but not most normal cells, making the enzyme an attractive target for anticancer therapy. The aim of this study was to address the breast cancer translational potential of the novel telomerase inhibitor, GRN163L. Experimental Design: In the present study, we investigated the effects of GRN163L treatment on a panel of breast cancer cells representing different tumor subtypes with varying genetic backgrounds, including ER+, ER-, HER2+, BRCA1 mutant breast tumor cells as well as doxorubicin-resistant cancer cells. To investigate the in vivo effects of GRN163L, we employed a breast cancer xenograft and metastasis model that simulates a clinical situation in which a patient arrives with a primary tumor that may be then treated or surgically removed. Results: GRN163L effectively inhibited telomerase activity in a dose-dependent fashion in all breast cancer cell lines resulting in progressive telomere shortening. A mismatch control oligonucleotide showed no effect on telomerase activity and GRN163L did not significantly affect telomere shortening in normal human mammary epithelial cells or in endothelial cells. Breast cancer cells that exhibited telomerase inhibition also exhibited significant reduction in colony formation and tumorigenicity. Furthermore, GRN163L suppressed tumor growth and lung metastases (P = 0.017) of MDA-MB-231 cells in vivo after 4 weeks of treatment. Conclusions:These results show in vivo effectiveness of GRN163L in breast cancer and support its promising clinical potential for breast cancer treatment.

Original languageEnglish
Pages (from-to)3184-3192
Number of pages9
JournalClinical Cancer Research
Volume12
Issue number10
DOIs
StatePublished - May 15 2006

Fingerprint

Telomerase
Telomere
Maintenance
Breast Neoplasms
Neoplasm Metastasis
Growth
Neoplasms
Telomere Shortening
Therapeutics
Heterografts
Oligonucleotides
Doxorubicin
Breast
Research Design
Endothelial Cells
Epithelial Cells
Cell Line
Lung
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. / Hochreiter, Amelia E.; Xiao, Hongling; Goldblatt, Erin M.; Gryaznov, Sergei M.; Miller, Kathy; Badve, Sunil; Sledge, George W.; Herbert, Brittney-Shea.

In: Clinical Cancer Research, Vol. 12, No. 10, 15.05.2006, p. 3184-3192.

Research output: Contribution to journalArticle

Hochreiter, Amelia E. ; Xiao, Hongling ; Goldblatt, Erin M. ; Gryaznov, Sergei M. ; Miller, Kathy ; Badve, Sunil ; Sledge, George W. ; Herbert, Brittney-Shea. / Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 10. pp. 3184-3192.
@article{0fe4372e2a604b5392803e32b7abfada,
title = "Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer",
abstract = "Purpose: Maintenance of telomeres by telomerase is critical for the continuing proliferation of most advanced cancer cells. Telomerase activity has been detected in the vast majority of cancer cells but not most normal cells, making the enzyme an attractive target for anticancer therapy. The aim of this study was to address the breast cancer translational potential of the novel telomerase inhibitor, GRN163L. Experimental Design: In the present study, we investigated the effects of GRN163L treatment on a panel of breast cancer cells representing different tumor subtypes with varying genetic backgrounds, including ER+, ER-, HER2+, BRCA1 mutant breast tumor cells as well as doxorubicin-resistant cancer cells. To investigate the in vivo effects of GRN163L, we employed a breast cancer xenograft and metastasis model that simulates a clinical situation in which a patient arrives with a primary tumor that may be then treated or surgically removed. Results: GRN163L effectively inhibited telomerase activity in a dose-dependent fashion in all breast cancer cell lines resulting in progressive telomere shortening. A mismatch control oligonucleotide showed no effect on telomerase activity and GRN163L did not significantly affect telomere shortening in normal human mammary epithelial cells or in endothelial cells. Breast cancer cells that exhibited telomerase inhibition also exhibited significant reduction in colony formation and tumorigenicity. Furthermore, GRN163L suppressed tumor growth and lung metastases (P = 0.017) of MDA-MB-231 cells in vivo after 4 weeks of treatment. Conclusions:These results show in vivo effectiveness of GRN163L in breast cancer and support its promising clinical potential for breast cancer treatment.",
author = "Hochreiter, {Amelia E.} and Hongling Xiao and Goldblatt, {Erin M.} and Gryaznov, {Sergei M.} and Kathy Miller and Sunil Badve and Sledge, {George W.} and Brittney-Shea Herbert",
year = "2006",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-05-2760",
language = "English",
volume = "12",
pages = "3184--3192",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer

AU - Hochreiter, Amelia E.

AU - Xiao, Hongling

AU - Goldblatt, Erin M.

AU - Gryaznov, Sergei M.

AU - Miller, Kathy

AU - Badve, Sunil

AU - Sledge, George W.

AU - Herbert, Brittney-Shea

PY - 2006/5/15

Y1 - 2006/5/15

N2 - Purpose: Maintenance of telomeres by telomerase is critical for the continuing proliferation of most advanced cancer cells. Telomerase activity has been detected in the vast majority of cancer cells but not most normal cells, making the enzyme an attractive target for anticancer therapy. The aim of this study was to address the breast cancer translational potential of the novel telomerase inhibitor, GRN163L. Experimental Design: In the present study, we investigated the effects of GRN163L treatment on a panel of breast cancer cells representing different tumor subtypes with varying genetic backgrounds, including ER+, ER-, HER2+, BRCA1 mutant breast tumor cells as well as doxorubicin-resistant cancer cells. To investigate the in vivo effects of GRN163L, we employed a breast cancer xenograft and metastasis model that simulates a clinical situation in which a patient arrives with a primary tumor that may be then treated or surgically removed. Results: GRN163L effectively inhibited telomerase activity in a dose-dependent fashion in all breast cancer cell lines resulting in progressive telomere shortening. A mismatch control oligonucleotide showed no effect on telomerase activity and GRN163L did not significantly affect telomere shortening in normal human mammary epithelial cells or in endothelial cells. Breast cancer cells that exhibited telomerase inhibition also exhibited significant reduction in colony formation and tumorigenicity. Furthermore, GRN163L suppressed tumor growth and lung metastases (P = 0.017) of MDA-MB-231 cells in vivo after 4 weeks of treatment. Conclusions:These results show in vivo effectiveness of GRN163L in breast cancer and support its promising clinical potential for breast cancer treatment.

AB - Purpose: Maintenance of telomeres by telomerase is critical for the continuing proliferation of most advanced cancer cells. Telomerase activity has been detected in the vast majority of cancer cells but not most normal cells, making the enzyme an attractive target for anticancer therapy. The aim of this study was to address the breast cancer translational potential of the novel telomerase inhibitor, GRN163L. Experimental Design: In the present study, we investigated the effects of GRN163L treatment on a panel of breast cancer cells representing different tumor subtypes with varying genetic backgrounds, including ER+, ER-, HER2+, BRCA1 mutant breast tumor cells as well as doxorubicin-resistant cancer cells. To investigate the in vivo effects of GRN163L, we employed a breast cancer xenograft and metastasis model that simulates a clinical situation in which a patient arrives with a primary tumor that may be then treated or surgically removed. Results: GRN163L effectively inhibited telomerase activity in a dose-dependent fashion in all breast cancer cell lines resulting in progressive telomere shortening. A mismatch control oligonucleotide showed no effect on telomerase activity and GRN163L did not significantly affect telomere shortening in normal human mammary epithelial cells or in endothelial cells. Breast cancer cells that exhibited telomerase inhibition also exhibited significant reduction in colony formation and tumorigenicity. Furthermore, GRN163L suppressed tumor growth and lung metastases (P = 0.017) of MDA-MB-231 cells in vivo after 4 weeks of treatment. Conclusions:These results show in vivo effectiveness of GRN163L in breast cancer and support its promising clinical potential for breast cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=33744799396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744799396&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2760

DO - 10.1158/1078-0432.CCR-05-2760

M3 - Article

VL - 12

SP - 3184

EP - 3192

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -